Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. Sacropenia and impaired cognitive function are two major contributors to frailty. This study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.
Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. The prevalence rates of frailty varies across countries, and the pooled estimates of prevalence rates of 52.3% and 40.2% of frailty and prefrailty were reported among nursing home residents respectively. Previous studies also revealed that frailty is predictive for various adverse health outcomes. Sacropenia is a major etiologic risk factor to frailty. It refers to an age-related generalised muscle disorder featuring with loss of muscle mass and function5. Talar et al systematically reviewed and meta-analysed 25 randomised controlled trials (RCTs) using resistance training among 2,267 older people (age \>65 years) with pre-sarcopenia, sarcopenia, pre-frailty or frailty. It was revealed that, compared to control, resistance training with at least 8 weeks intervention period had small to large effects in improving handgrip strength, lower-limb strength, agility, gait speed, postural stability, functional performance, fat mass and muscle \[Effect size (ES) = 0.29 - 0.93, p \<0.001 to = 0.007\]. Cognitive impairment is another major risk factor for declined frailty status among prefrail older people. Non-frail older people are known to have better performance on cognitive status, including processing speed, executive function, attention and working memory, immediate memory and delayed memory (g = 0.320 to 0.64), than frail older people. Ample research evidence suggested that cognition predicts the incidence of frailty. Exergaming is a fast growing research trend in gerontechnology and several commercial exergaming consoles, such as the Xbox system (including Xbox One and Xbox 360) and Nintendo Will (Wii Sports and Wii Fit), are available. Ogawa et al systematically reviewed 7 clinical trials (5 RCTs and 2 uncontrolled studies) and revealed that exergaming could improve cognitive functions, including executive function, process speed and reaction time, of older people. Moreover, a recent RCT revealed that, compared with the combined use of exercise (resistance, aerobic and balance training), a 12 week Kinect-based exergaming could better improve the global cognition \[F(1, 44) = 5.277, p = 0.026\] as measured by the Montreal Cognitive Assessment of community-frail older people. The Kinect-based group (n = 25) also demonstrated significant improvement in verbal (p \< 0.05) and working (p \< 0.05) memory post-intervention but the combined exercise group (n = 21) did not. Given that sacropenia and impaired cognitive function are 2 major contributors to frailty; and exergaming and resistance training are effective treatments in improving the cognitive function and sacropenia of older people respectively, this study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
30
In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software "Nintendo Switch Sports" will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training.
The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
Jockey club Institute of Health
Ho Man Tin, Hong Kong
Muscle quantity, higher score means better muscle quantity
Will be assessed using a bioelectrical impedance measurement
Time frame: T1: baseline (before the study begins)
Change from baseline muscle quantity at 6 weeks, higher score means better muscle quantity
Will be assessed using a bioelectrical impedance measurement
Time frame: T2: mid-intervention (week 6)
Change from baseline muscle quantity at 12 weeks, higher score means better muscle quantity
Will be assessed using a bioelectrical impedance measurement
Time frame: T3: post-intervention (week 12)
Change from baseline muscle quantity at 16 weeks, higher score means better muscle quantity
Will be assssed using a bioelectrical impedance measurement
Time frame: T4: 1 month follow up (week 16)
Change from baseline muscle quantity at 24 weeks, higher score means better muscle quantity
Will be assssed using a bioelectrical impedance measurement
Time frame: T5: 3 months follow up (week 24)
Muscle strength, higher score means better muscle strength
Will be assessed using a handheld dynamometer
Time frame: T1: baseline (before the study begins)
Change from baseline muscle strength at 6 weeks, higher score means better muscle strength
Will be assessed using a handheld dynamometer
Time frame: T2: mid-intervention (week 6)
Change from baseline muscle strength at 12 weeks, higher score means better muscle strength
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Will be assessed using a handheld dynamometer
Time frame: T3: post-intervention (week 12)
Change from baseline muscle strength at 16 weeks, higher score means better muscle strength
Will be assessed using a handheld dynamometer
Time frame: T4: 1 month follow up (week 16)
Change from baseline muscle strength at 24 weeks, higher score means better muscle strength
Will be assessed using a handheld dynamometer
Time frame: T5: 3 months follow up (week 24)
Lower Extremity functions, score ranged from 0-12, higher scores mean better lower extremity functions
Will be assessed using the Short Physical Performance Battery
Time frame: T1: baseline (before the study begins)
Change from baseline lower extremity functions at 6 weeks, score ranged from 0-12, higher scores mean better lower extremity functions
Will be assessed using the Short Physical Performance Battery
Time frame: T2: mid-intervention (week 6)
Change from baseline lower extremity functions at 12 weeks, score ranged from 0-12, higher scores mean better lower extremity functions
Will be assessed using the Short Physical Performance Battery
Time frame: T3: post-intervention (week 12)
Change from baseline lower extremity functions at 16 weeks, score ranged from 0-12, higher scores mean better lower extremity functions
Will be assessed using the Short Physical Performance Battery
Time frame: T4: 1 month follow up (week 16)
Change from baseline lower extremity functions at 24 weeks, score ranged from 0-12, higher scores mean better lower extremity functions
Will be assessed using the Short Physical Performance Battery
Time frame: T5: 3 months follow up (week 24)
Cognitive function, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition
Will be assessed using the Montreal Cognitive Assessment (HK version)
Time frame: T1: baseline (before the study begins)
Change from baseline cognitive function at 6 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition
Will be assessed using the Montreal Cognitive Assessment (HK version)
Time frame: T2: mid-intervention (week 6)
Change from baseline cognitive function at 12 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition
Will be assessed using the Montreal Cognitive Assessment (HK version)
Time frame: T3: post-intervention (week 12)
Change from baseline cognitive function at 16 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition
Will be assessed using the Montreal Cognitive Assessment (HK version)
Time frame: T4: 1 month follow up (week 16)
Change from baseline cognitive function at 24 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition
Will be assessed using the Montreal Cognitive Assessment (HK version)
Time frame: T5: 3 months follow up (week 24)
Mobility, longer time means worse functional mobility
Will be assessed using the Timed Up and Go Test
Time frame: T1: baseline (before the study begins)
Change from baseline mobility at 6 weeks, longer time means worse functional mobility
Will be assessed using the Timed Up and Go Test
Time frame: T2: mid-intervention (week 6)
Change from baseline mobility at 12 weeks, longer time means worse functional mobility
Will be assessed using the Timed Up and Go Test
Time frame: T3: post-intervention (week 12)
Change from baseline mobility at 16 weeks, longer time means worse functional mobility
Will be assessed using the Timed Up and Go Test
Time frame: T4: 1 month follow up (week 16)
Change from baseline mobility at 24 weeks, longer time means worse functional mobility
Will be assessed using the Timed Up and Go Test
Time frame: T5: 3 months follow up (week 24)
Frailty, score range 0 to 9, higher score means higher level of frailty
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Time frame: T1: baseline (before the study begins)
Change from baseline frailty at 6 weeks, score range 0 to 9, higher score means higher level of frailty
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Time frame: T2: mid-intervention (week 6)
Change from baseline frailty at 12 weeks, score range 0 to 9, higher score means higher level of frailty
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Time frame: T3: post-intervention (week 12)
Change from baseline frailty at 16 weeks, score range 0 to 9, higher score means higher level of frailty
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Time frame: T4: 1 month follow up (week 16)
Change from baseline frailty at 24 weeks, score range 0 to 9, higher score means higher level of frailty
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
Time frame: T5: 3 months follow up (week 24)
Sarcopenia, score ranged from 0 to 20, lower score means lower risk
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
Time frame: T1: baseline (before the study begins)
Change from baseline sarcopenia at 6 weeks, score ranged from 0 to 20, lower score means lower risk
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
Time frame: T2: mid-intervention (week 6)
Change from baseline sarcopenia at 12 weeks, score ranged from 0 to 20, lower score means lower risk
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
Time frame: T3: post-intervention (week 12)
Change from baseline sarcopenia at 16 weeks, score ranged from 0 to 20, lower score means lower risk
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
Time frame: T4: 1 month follow up (week 16)
Change from baseline sarcopenia at 24 weeks, score ranged from 0 to 20, lower score means lower risk
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
Time frame: T5: 3 month follow up (week 16)